Technology 85 of 266
Drug formulation
6 EIC Accelerator winners build on Drug formulation, 1% of the classified companies, in 1 sector and 2 industries.
6
Companies
1
Sectors
2
Industries
5
Countries
0%
Exits
0%
Show signs of scaling
Sectors
- Health6 (100%)
Industries
Used together with
Other technologies of the same companies
Companies per year of first award
2019
2020
2021
2022
2023
2024
- Drug formulation
Show the numbers
| Companies | Drug formulation | |
|---|---|---|
| 2019 | 0 | 0 |
| 2020 | 1 | 1 |
| 2021 | 0 | 0 |
| 2022 | 3 | 3 |
| 2023 | 2 | 2 |
| 2024 | 0 | 0 |
What happened to them (6 of 6 checked)
- Active5 (83%)
- Exit0 (0%)
- Failed1 (17%)
- Other0 (0%)
Signs of scaling
- Scaling0 (0%)
- Not scaling1 (17%)
- Scaling unclear5 (83%)
Keywords
- Alzheimer's disease
- Antibiotic-free treatment
- ARDS
- Bacterial vaginosis
- Cerebral amyloid angiopathy
- COVID-19
- Dementia
- Drug reformulation
- Drug repurposing
- Epilepsy
- Focal cortical dysplasia
- Gut maturation
- Imatinib
- Lung fibrosis
- Neonatology
- Oral insulin
- pH modulation
- Premature infants
- Pulmonary arterial hypertension
- Rare diseases
- Thromboxane receptor
- Vaginal microbiome
- Women's health
All 6 companies using Drug formulation
| Company | Project | Industry | Country | Cut-off | Funding | Status | Rasph |
|---|---|---|---|---|---|---|---|
| GEDEA BIOTECH AB | pHyphBreakthrough dual-action OTC tablet for treatment and prevention of both bacterial and fungal vaginitis | Medical devices | Sweden | November 2023 | Blended finance | Active | Deep dive |
| Panntherapi | PANNEXINPannexin 1 – a novel target for pediatric orphan epilepsy | Biopharmaceuticals | France | March 2023 | Grant first | Active | Deep dive |
| Arctic Therapeutics ehf | DNACADementia/Alzheimer Drug Attributed to Cystatin-C and other mutations – precision medicine drug development | Biopharmaceuticals | Iceland | October 2022 | Blended finance | Active | Deep dive |
| ATXA Therapeutics Ltd | PAH-AdvancePAH-ADVANCE: Accelerating the Clinical Path of NTP42, a disease-modifying drug that will disrupt the future treatment of cardiopulmonary diseases, including pulmonary arterial hypertension (PAH). | Biopharmaceuticals | Ireland | June 2022 | Blended finance | Active | Deep dive |
| ELGAN Pharma Ltd. | ELGN-GIA first-in-class therapy for intestinal malabsorption in premature newborns | Biopharmaceuticals | Israel | June 2022 | Grant first | Active | Deep dive |
| Exvastat Ltd | ImpentriFirst effective pharmacotherapy for ARDS to lower mortality and improve quality of life of patients. | Biopharmaceuticals | Ireland | March 2020 | Grant only | Closed | Deep dive |